RxDoctor Payments Data

Sanjiv Jindia, MD

Anesthesiology · Lafayette, LANPI 1316934466

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 28 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Pacira Pharmaceuticals Incorporated at 26.6% of the total. Reporting peaked in 2019 at $287 and has fallen 69.9% since, to $87 in 2025.

$816in general payments, 2019–2025

Across 28 payments — averaging $29.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pacira Pharmaceuticals Incorporated$217
  • Abbott$200
  • Medtronic$161
  • Boston Scientific$42
  • Nevro Corp.$34
  • Acacia Pharma Inc$30
  • plus $132 from 7 others

What the payments were for

  • Food & beverage$816100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$816 in reported general payments places this provider in the 85th percentile of 497 anesthesiology providers in Louisiana.

See all anesthesiology providers in Louisiana

Medicare billing

Part B allowed, 2024
$76,936
Medicare patients
218
Services billed
813

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,273$25,834
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen522$14,053
LinzessLinaclotide19$9,573
Xtampza ErOxycodone Myristate12$8,022
Gabapentin815$7,704
Oxycodone Hcl385$7,645
Hydrocortisone Butyrate12$6,983
MovantikNaloxegol Oxalate15$5,762
Morphine Sulfate ErMorphine Sulfate196$4,817
Baclofen528$4,703
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc30$4,424
Lidocaine-PrilocaineLidocaine/Prilocaine64$4,268
Fentanyl42$3,304
Betamethasone Dipropionate22$2,749
Pregabalin285$2,440

Paid to pharmacies, not to this prescriber.

Other anesthesiology in Lafayette

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →